Cytogenetic Prognostication Within Medulloblastoma Subgroups

Autor: Franck Bourdeaut, Michael K. Cooper, Almos Klekner, Stefan Rutkowski, David Shih, Jeffrey R. Leonard, Simon Bailey, Concezio Di Rocco, Ulrich Schüller, Giuseppe Cinalli, Pim J. French, Cinzia Lavarino, Young Shin Ra, John Peacock, Yuan Yao, A. Sorana Morrissy, William A. Weiss, Nanne K. Kloosterhof, László Bognár, Pasqualino De Antonellis, Teiji Tominaga, Stephen W. Scherer, Paul A. Northcott, David T.W. Jones, Reid C. Thompson, Shenandoah Robinson, Marta Perek-Polnik, Boleslaw Lach, Massimo Zollo, Olivier Delattre, Jennifer A. Chan, Janet C. Lindsey, Xin Wang, Nada Jabado, Karel Zitterbart, David Malkin, Adi Rolider, Roger J. Packer, James M. Olson, Steffen Albrecht, Ji Yeoun Lee, Wiesława Grajkowska, Charles G. Eberhart, Marcel Kool, Vijay Ramaswamy, Seung-Ki Kim, Joanna J. Phillips, Andrey Korshunov, Michael D. Taylor, Florence M.G. Cavalli, Luca Massimi, Xiaochong Wu, Maryam Fouladi, Peter Hauser, Xing Fan, Steven C. Clifford, Leos Kren, Carmen de Torres, Erna M.C. Michiels, Adrian M. Dubuc, Amar Gajjar, Livia Garzia, Eric Bouffet, Ian F. Pollack, Marc Remke, Jaume Mora, Claudia C. Faria, Miklós Garami, Erwin G. Van Meir, Byung Kyu Cho, Karin M. Muraszko, Joshua B. Rubin, Anne Jouvet, Stefan M. Pfister, Nalin Gupta, Johan M. Kros, Shin Jung, Yoon Jae Cho, Rajeev Vibhakar, Linda M. Liau, Stephen C. Mack, Scott L. Pomeroy, Betty Luu, Cynthia Hawkins, Ali G. Saad, Kyu-Chang Wang, Uri Tabori, Michelle Fèvre-Montange, Adam M. Fontebasso, Robert J. Wechsler-Reya, Toshihiro Kumabe, James T. Rutka, François Doz

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 32, iss 9
Journal of Clinical Oncology, 32(9), 886-+. American Society of Clinical Oncology

Purpose Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3, and Group 4. Current medulloblastoma protocols stratify patients based on clinical features: patient age, metastatic stage, extent of resection, and histologic va

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0b446bdc999aa43ff7dd6176c0e742a
http://hdl.handle.net/11588/577671

Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma.

Autor: Borgenvik A; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Holmberg KO; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Bolin S; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Zhao M; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Savov V; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Rosén G; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Hutter S; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Garancher A; Tumor Initiation & Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, San Diego, California., Rahmanto AS; Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden., Bergström T; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Olsen TK; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Mainwaring OJ; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Sattanino D; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Verbaan AD; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Rusert JM; Tumor Initiation & Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, San Diego, California., Sundström A; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Bravo MB; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Dang Y; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Biomedical Centre, Uppsala University, Uppsala, Sweden., Wenz AS; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Biomedical Centre, Uppsala University, Uppsala, Sweden., Richardson S; Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle upon Tyne, United Kingdom., Fotaki G; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Hill RM; Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle upon Tyne, United Kingdom., Dubuc AM; The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada., Kalushkova A; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Remke M; The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada., Čančer M; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Jernberg-Wiklund H; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Giraud G; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Chen X; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Biomedical Centre, Uppsala University, Uppsala, Sweden., Taylor MD; The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada., Sangfelt O; Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden., Clifford SC; Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle upon Tyne, United Kingdom., Schüller U; Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Department of Paediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Research Institute Children's Cancer Center Hamburg, Hamburg, Germany., Wechsler-Reya RJ; Tumor Initiation & Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, San Diego, California., Weishaupt H; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., Swartling FJ; Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

Publikováno v: Cancer research [Cancer Res] 2022 Dec 16; Vol. 82 (24), pp. 4586-4603.

A molecularly integrated grade for meningioma.

Autor: Driver J; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Hoffman SE; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Harvard-MIT Program in Health Science Technology, MD-PhD Program, Harvard Medical School, Boston, Massachusetts, USA., Tavakol S; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Woodward E; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Maury EA; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Harvard-MIT Program in Health Science Technology, MD-PhD Program, Harvard Medical School, Boston, Massachusetts, USA.; Bioinformatics and Integrative Genomics Program, Harvard Medical School, Boston, Massachusetts, USA., Bhave V; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Greenwald NF; Cancer Biology Program, Stanford University School of Medicine, Stanford, California, USA., Nassiri F; Department of Neurosurgery, University of Toronto, Toronto, Ontario, Canada., Aldape K; National Cancer Institute, Bethesda, Maryland, USA., Zadeh G; Department of Neurosurgery, University of Toronto, Toronto, Ontario, Canada., Choudhury A; Departments of Radiation Oncology and Neurological Surgery, University of California San Francisco, San Francisco, California, USA., Vasudevan HN; Departments of Radiation Oncology and Neurological Surgery, University of California San Francisco, San Francisco, California, USA., Magill ST; Departments of Radiation Oncology and Neurological Surgery, University of California San Francisco, San Francisco, California, USA., Raleigh DR; Departments of Radiation Oncology and Neurological Surgery, University of California San Francisco, San Francisco, California, USA., Abedalthagafi M; King Fahad Medical City and King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia., Aizer AA; Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Alexander BM; Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Ligon KL; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Reardon DA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Al-Mefty O; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Ligon AH; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Dubuc AM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Beroukhim R; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Claus EB; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Yale School of Public Health, New Haven, Connecticut, USA., Dunn IF; Department of Neurosurgery, Oklahoma University Medical Center, Oklahoma City, Oklahoma, USA., Santagata S; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Bi WL; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Publikováno v: Neuro-oncology [Neuro Oncol] 2022 May 04; Vol. 24 (5), pp. 796-808.

Re-evaluating tumors of purported specialized prostatic stromal origin reveals molecular heterogeneity, including non-recurring gene fusions characteristic of uterine and soft tissue sarcoma subtypes.

Autor: Acosta AM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. aacosta4@bwh.harvard.edu., Sholl LM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Dickson BC; Department of Pathology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada., McKenney JK; Department of Pathology, Robert J. Tomsich Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA., Gordetsky JB; Department of Pathology, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA., Pins MR; Department of Pathology, Advocate Lutheran General Hospital, Chicago Medical School, Park Ridge, IL, USA., Marino-Enriquez A; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Dong F; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Dubuc AM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Cin PD; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Fletcher CDM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Publikováno v: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2021 Sep; Vol. 34 (9), pp. 1763-1779. Date of Electronic Publication: 2021 May 13.

Twists and turns from "tumor in tumor" profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis.

Autor: Terraf P; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA., Sholl LM; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA., Awad MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA., Garcia EP; Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA., MacConaill LE; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA., Dal Cin P; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA., Kim A; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA., Lindeman NI; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA., Stachler M; Department of Pathology, University of California San Francisco, San Francisco, California 94143, USA., Hwang DH; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA., Dubuc AM; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.

Publikováno v: Cold Spring Harbor molecular case studies [Cold Spring Harb Mol Case Stud] 2021 Aug 02; Vol. 7 (4). Date of Electronic Publication: 2021 Aug 02 (Print Publication: 2021).